USSTOCK.TODAY
Pre-Market
Log in Sign up

Tiziana Life Sciences to Present Intranasal Foralumab Program at BIO-Europe 2026

Proactive +1 · ·by G4L

TLSA
TLSA Tiziana Life Sciences Ltd
$0.67 -2.86%
View chart & analysis →
  1. 1Tiziana Life Sciences Ltd will present its intranasal Foralumab program at BIO-Europe 2026.
  2. 2CEO Ivo Elpi will present the program.
  3. 3Management and the business development team will hold one-on-one meetings with potential strategic partners, investors, and collaborators.

So what's the key point?

Tiziana Life Sciences is announcing a new treatment that is administered through the nose. Management is meeting with investors to find people to partner with for the business.

Source Proactive +1 · View original ↗

Related 3-line summaries

Tiziana Life Sciences (TLSA) to Present BANYAN Phase 2a Poster at ALS Nexus Proactive +1 · Aug 25Abeona Therapeutics beats consensus with Q3 loss of $0.08 per share Nasdaq +1 · 10h agoIspire Technology Inc. Announces First Quarter Financial Results Ended September 30, 2026 ACCESSWIRE +1 · 10h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news